Hypomethylating agent

This page covers all Hypomethylating agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA methyltransferase (DNMT), DNA methyltransferase, DNA methyltransferase 1 (DNMT1).

Targets

DNA methyltransferase (DNMT) · DNA methyltransferase · DNA methyltransferase 1 (DNMT1) · DNA methyltransferases

Marketed (1)

• Decitabine and cedazuridine · Race Oncology Ltd · Oncology
  Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while cedazuridine protects decitabine from deamination, allowing oral administration.

Phase 3 pipeline (2)

• Subcutaneous azacitidine · Otsuka Australia Pharmaceutical Pty Ltd · Oncology
  Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase enzymes, leading to increased expression of tumor suppressor genes.
• ASTX727 · Taiho Oncology, Inc. · Oncology
  ASTX727 is a fixed-dose combination of decitabine and cedazuridine that inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes in myelodysplastic syndrome.

Phase 2 pipeline (4)

• BP1001 plus decitabine · Bio-Path Holdings, Inc. · Oncology
  Decitabine is a hypomethylating agent that targets DNA methyltransferase 1 (DNMT1)
• Azacitidine Injection [Vidaza] · Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias · Oncology
  Inhibits DNA methyltransferase
• Azacitidine associated with Valproic acid · Assistance Publique - Hôpitaux de Paris · Oncology
  Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferases, leading to increased expression of tumor suppressor genes.
• 5-Azacitidine · Shirley Ryan AbilityLab · Oncology
  Inhibits DNA methyltransferase

Phase 1 pipeline (1)

• ABT-348 and azacitidine · AbbVie (prior sponsor, Abbott) · Oncology
  AZA is a hypomethylating agent that targets DNA methyltransferase enzymes.